[Liver fibrosis: from pathophysiology to therapeutic openings].
Understanding of liver fibrosis pathogenesis has undergone tremendous advances over the past twenty years. In this respect, demonstration of the reversibility of fibrosis was a major turnpoint. The panel of therapeutic targets is continuously expanding. Clinical development has however remained limited, heretofore, but should rapidly progress owing to the availability of accurate non-invasive methods for assessment of fibrosis, to improvement in the selection patients included in therapeutic trials, and to the development of cell specific targeting devices for agents at risk of adverse effects.
Mallat
A
A
Service d'Hépatologie et de Gastroentérologie, Groupe Hospitalier Henri-Mondor-Albert-Chenevier, Assistance Publique-Hôpitaux de Paris, 94010 Créteil cedex, France. ariane.mallat@hmn.aphp.fr
Lotersztajn
S
S
D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy*